NDA 050767 · Pfizer
Cleocin
Clindamycin Phosphate · Vaginal
Last checked: Nov 19, 2026Latest source record: Jul 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Aug 13, 1999
Approved uses
1
Original approval plus efficacy supplements
Registered trials
274
66 Phase 3, 28 recruiting
FAERS reports
4,923
2,973 serious, 353 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 9, 2026.
INDICATIONS AND USAGE CLEOCIN Vaginal Ovules are indicated for 3-day treatment of bacterial vaginosis in non-pregnant women. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women. NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , Neisseria gonorrhoeae , Candida albicans , and herpes simplex virus, should be ruled out.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- CLEOCIN · CLINDAMYCIN PHOSPHATE 100MG · SUPPOSITORY, VAGINAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clindamycin" as an intervention, any sponsor and status, largest first.
- Staphylococcus Aureus Network Adaptive Platform TrialPivotal-lookingRecruiting
University of MelbourneAcademic, hospital or other
NCT05137119 · 8,000 participants (planned) · Start Feb 16, 2022 · Primary completion Dec 1, 2028
Drug: Cefazolin; Penicillin and 2 more · For: Staphylococcus Aureus Bacteremia
Sites: Houston, Texas; Garran, Australia; Blacktown, Australia · 161 sites in all
University of OxfordAcademic, hospital or other
NCT04093765 · 5,542 participants · Start Nov 1, 2018 · Primary completion Dec 31, 2019
Drug: Antimalarials · For: Plasmodium Falciparum Malaria
Sites: Mae Sot, Thailand
- Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial VaginosisPivotal-lookingCompleted
University Hospital, LilleAcademic, hospital or other
NCT00642980 · 3,105 participants · Start Apr 2006 · Primary completion Jun 2011
Drug: Clindamycin; Placebo and 1 more · For: Pregnancy
Sites: Lille, France
- Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00729937 · 2,265 participants · Start Apr 2009 · Primary completion May 2013
Drug: Cephalexin; Clindamycin and 1 more · For: Staphylococcal Infection
Sites: Phoenix, Arizona; Sylmar, California; Baltimore, Maryland · 5 sites in all
- Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated MalariaPivotal-lookingCompleted
Universiteit AntwerpenAcademic, hospital or other
NCT01374581 · 2,117 participants · Start May 2012 · Primary completion Jun 2014
Drug: Artemether/Lumefantrine; Artesunate/Amodiaquine and 1 more · For: Malaria
Sites: Kinshasa, Republic of the Congo; Kiruhura, Uganda
- Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean InfectionPivotal-lookingCompleted
Alan TitaAcademic, hospital or other
NCT01235546 · 2,013 participants · Start May 2011 · Primary completion Dec 2015
Drug: Azithromycin and standard of care; Placebo and standard of care · For: Endometritis; Wound Infection; Abscess and 1 more
Sites: Birmingham, Alabama; New Orleans, Louisiana; Jackson, Mississippi · 9 sites in all
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center TrialPivotal-lookingCompleted
Duke UniversityAcademic, hospital or other
NCT03283878 · 1,770 participants · Start Oct 24, 2017 · Primary completion Nov 20, 2024
Drug: Cefazolin · For: Arthropathy of Knee; Antibiotic Prophylaxis
Sites: San Francisco, California; Atlanta, Georgia; Towson, Maryland · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity554
- drug ineffective431
- rash366
- diarrhoea320
- nausea281
- off label use263
- pain251
- fatigue245
- pruritus207
- dyspnoea185
- headache173
- pyrexia162
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 39 |
| 2005 | 90 |
| 2006 | 82 |
| 2007 | 23 |
| 2008 | 42 |
| 2009 | 84 |
| 2010 | 184 |
| 2011 | 110 |
| 2012 | 136 |
| 2013 | 188 |
| 2014 | 185 |
| 2015 | 240 |
| 2016 | 401 |
| 2017 | 280 |
| 2018 | 377 |
| 2019 | 366 |
| 2020 | 283 |
| 2021 | 231 |
| 2022 | 318 |
| 2023 | 334 |
| 2024 | 316 |
| 2025 | 336 |
| 2026 | 276 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cleocin (Clindamycin Phosphate)
2024 spending
$120K
Beneficiaries
374
479 claims
Per beneficiary
$320
$57.82 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $201,437 |
| 2021 | $186,964 |
| 2022 | $165,478 |
| 2023 | $166,113 |
| 2024 | $119,524 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antibiotic regimens for postpartum endometritis.
Mackeen AD, Packard RE, Ota E, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Polyspecific Intravenous Immunoglobulin in Clindamycin-treated Patients With Streptococcal Toxic Shock Syndrome: A Systematic Review and Meta-analysis.
Parks T, Wilson C, Curtis N, et al. · Clin Infect Dis 2018 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Efficacy of topical treatments for mild-to-moderate acne: A systematic review and meta-analysis of randomized control trials.
Kakpovbia EE, Young T, Milam EC, et al. · J Eur Acad Dermatol Venereol 2025 · Systematic Review, Network Meta-Analysis
- Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.
Liu H, Yu H, Xia J, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Linezolid versus clindamycin for toxin inhibition in severe skin and soft tissue infections: a systematic review and meta-analysis.
Stropes A, Lautenschlager C, Smith A, et al. · Infection 2026 · Systematic Review, Meta-Analysis
- Topical benzoyl peroxide for acne.
Yang Z, Zhang Y, Lazic Mosler E, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.